Customize
Quick Links
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
Regus World Trade Centre
Muelle de Barcelona, edif. Sur, 2ª Planta
Barcelona Cataluña
08039 Spain
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

4th Annual European Congress on Hematology™: Focus on Leukemia, Lymphoma, and Myeloma

4th Annual European Congress on Hematology™: Focus on Leukemia, Lymphoma, and Myeloma


7-9 February 2019
Barcelona, Spain

Hilton Barcelona
589-591 Avenida Diagonal
Barcelona, Spain 08014

Overview

We are pleased to announce the 4th Annual European Congress on Hematology™: Focus on Leukemia, Lymphoma, and Myeloma. At this congress, clinicians will be able to enhance their skills to contextualize the wealth of emerging data on how to treat hematologic malignancies, update their clinical decision-making based upon individual patient/tumor characteristics and mitigation of adverse events, and learn how to apply novel management strategies in their practices to improve patient outcomes.

Our abilities to characterize tumors, stratify risk with evolving testing technologies, and manage leukemic, lymphoid and myeloid malignancies continue to change at a rapid pace. Sophisticated molecular techniques, which are used to individualize risk stratification and guide treatment, along with novel targeted and immunotherapeutic options, have expanded the treatment armamentarium in the field. Given the realities of contemporary practice, practitioners can have difficulty placing practice-changing data into its proper clinical context and applying these strategies to evolving treatment paradigms in the setting of hematologic malignancies. It also remains a challenge for oncologists and hematologists to attend national and international oncology society meetings where fast-paced practice-changing information is typically presented, resulting in an inability for them to maintain state-of-the-art care for their patients.

The congress is organized in an exciting case-based format, in which leading international experts will participate in informative lectures and panels that will discuss recent data sets. What sets this meeting apart are the interactive discussions in which participants will be challenged to engage directly with renowned faculty to share their perspectives, experiences, and methods for addressing clinical challenges in the management of leukemic, lymphoid, and myeloid malignancies.

Benefits of Attending

  • Place practice-changing data in its proper clinical context
  • Network with top hematologists, clinicians, and scientists
  • Apply novel management strategies to your practice to improve patient outcomes
  • Participate in an exciting case-based format about current challenges and controversies
  • Incorporate evolving treatment paradigms into the setting of hematologic malignancies
  • Update your clinical decision-making based upon individual patient/tumor characteristics

Target Audience

This educational activity is directed toward healthcare professionals who practice primarily outside of the United States. It is specifically designed for medical oncologists and other healthcare professionals (eg, physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants) involved in the treatment and management of patients with hematologic malignancies.

Learning Objectives:

After successful completion of this educational activity, you should be better prepared to:

  • Assess current and emerging risk-stratification methods and response criteria using genomic, molecular, and clinical biomarkers, and how they can be used to guide clinical decision-making in the management of leukemia, lymphoma, and myeloma malignancies
  • Differentiate the mechanism of action, safety, and efficacy of current and emerging targeted and cancer immunotherapies used or investigated in various types of leukemia, lymphoid, and myeloma malignancies
  • Assess landmark clinical trial results in the context of how they impact evolving clinical practice paradigms, and can be applied to personalize care and optimize outcomes
  • Identify interprofessional approaches to addressing treatment-related toxicities in patients who receive care for leukemic, lymphoid, and myeloid malignancies
  • Evaluate effective strategies to assess and address nonadherence to oral oncolytic therapies
  • Interpret recent clinical trial findings concerning novel compounds or strategies to manage leukemic, lymphoid, and myeloid malignancies
  • Explain the therapeutic implications of emerging data on evolving treatment paradigms for patients with leukemia, lymphoma, and myeloma malignancies in newly diagnosed and relapsed/refractory settings

Program Chair

Anas Younes, MD
Professor and Chief, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY, USA
 

Co-Chairs

Paolo Ghia, MD, PhD
Associate Professor
Università Vita-Salute San Raffaele
Director, Strategic Research Program on CLL
IRCCS San Raffaele Scientific Institute
Milan, Italy

Gilles A. Salles, MD, PhD
University Professor
Head of Hematology
Claude Bernard University of Lyon
Hospices Civils de Lyon
Lyon, France

Srdan Verstovsek, MD, PhD
Medical Oncologist and Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA
 

Local Organizing Committee

Véronique Leblond, MD
Head of the Department of Hematology
Pitié-Salpêtrière Hospital
Paris, France
 
 

Marek Trněný, MD, CSc
Chairman
Department of Medicine
Charles University General Hospital
Prague, Czech Republic
 







Become a Member

Forgot Password?
Filter By